Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation.
about
The aging spine: new technologies and therapeutics for the osteoporotic spineHas tamoxifen had its day?Endocrinology and hormone therapy in breast cancer: selective oestrogen receptor modulators and downregulators for breast cancer - have they lost their way?Patterns of reduced nipple aspirate fluid production and ductal lavage cellularity in women at high risk for breast cancer.Molecular cancer prevention: Current status and future directionsThe Effect of Menopausal Hormone Therapies on Breast Cancer: Avoiding the RiskBreast cancer chemoprevention: old and new approachesNonsurgical Treatment Strategies after Osteoporotic Hip Fractures.Cancer chemoprevention: Much has been done, but there is still much to do. State of the art and possible new approachesMedical prevention of breast cancerLasofoxifene, a new selective estrogen receptor modulator for the treatment of osteoporosis and vaginal atrophyCancer chemoprevention with dietary isothiocyanates mature for clinical translational researchRaloxifene and breast cancerEffect of raloxifene on IGF-I and IGFBP-3 in postmenopausal women with breast cancerPrevention of breast cancer in postmenopausal women: approaches to estimating and reducing riskAtypical hyperplasia of the breast--risk assessment and management options.Breast-related effects of selective estrogen receptor modulators and tissue-selective estrogen complexesMolecular mechanisms and treatment of bone metastasis.Ductal carcinoma in situ of the breast: a surgical perspective.Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data.Ongoing data from the breast cancer prevention trials: opportunity for breast cancer risk reduction.Risk-benefit profile for raloxifene: 4-year data From the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial.Ongoing Use of Data and Specimens From National Cancer Institute-Sponsored Cancer Prevention Clinical Trials in the Community Clinical Oncology Program.Cost-effectiveness of preventative therapies for postmenopausal women with osteopeniaPharmacology and clinical applications of selective estrogen receptor modulators.Current strategies for the prevention of breast cancerPIK3CA and TP53 gene mutations in human breast cancer tumors frequently detected by ion torrent DNA sequencing.Preventing fractures in elderly people.Mammary cancer chemoprevention by withaferin A is accompanied by in vivo suppression of self-renewal of cancer stem cellsLasofoxifene: Evidence of its therapeutic value in osteoporosis.Is Endocrine Therapy Really Pleasant? Considerations about the Long-Term Use of Antihormonal Therapy and Its Benefit/Side Effect RatioClinician's Guide to Prevention and Treatment of OsteoporosisLong-term safety and efficacy of raloxifene in the prevention and treatment of postmenopausal osteoporosis: an update.2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada.Anti-breast cancer potential of SS5020, a novel benzopyran antiestrogenArzoxifene: the evidence for its development in the management of breast cancer.Selective estrogen receptor modulators and the combination therapy conjugated estrogens/bazedoxifene: A review of effects on the breast.Differential induction of quinone reductase by phytoestrogens and protection against oestrogen-induced DNA damageNCCN Task Force Report: Bone Health in Cancer Care.Tamoxifen for breast cancer chemoprevention: low uptake by high-risk women after evaluation of a breast lump
P2860
Q24609687-045B0090-FFCC-4016-BFD0-FE163D1EF203Q24800161-BF29536A-331A-496C-B9C9-078DAD0DE74EQ24810287-069CB23F-855E-4E78-A7CE-AE8AA9B17F93Q25257326-66AC3409-87A5-490D-9B9D-099E876AA6B1Q26797207-D98DD737-BD4C-4FC4-B59B-21F5E27FB1DEQ26821782-EDCCD65F-1F5C-4A6C-B0FC-84E86EBBF329Q27693259-779DC600-CE37-413C-BD48-819556829D09Q27693845-09EF33CE-8715-4A65-998A-75DBE02BA9A2Q28080472-7376F931-DA01-4E26-AF56-D32B01355DF4Q28086915-47D458C4-FEED-4A8D-8FD4-F5E9DD344CC3Q28253298-9B4EB9B4-E851-4E9E-9037-6F61063841C5Q28269727-10F5E533-895B-4C83-A26B-4658F9FEF3C1Q28361457-C8548EA5-DD85-45C9-8A0A-09F24C69146CQ28366565-CD9CC227-2FC2-4530-815B-84AC12710870Q28390064-1133399D-169B-48BF-9FA3-640C3E120B57Q30301033-3F1831CA-B3B8-4E7C-A8F4-82441A2C9AA5Q30409045-356AB366-9DC8-47DE-8DF3-6717095A47D7Q30445717-3AC5AEBF-43C3-4D66-9707-4B1AFA30FF0AQ30463534-2494CBE3-FBAD-4173-90C5-08390522C10AQ30620889-AB37B1FB-FC18-4660-BB2E-FE6741266373Q30936399-BAACF626-5891-4667-AC28-4B0AADDACF91Q30940476-C23D208B-5D3B-45B0-AEB1-F11E58F69285Q31001228-A663D17F-890B-4B25-924B-5DA07C2E7FDAQ33282322-4D927B8F-AB8A-450E-B343-8BB03E1AB1C8Q33384192-9C087BB2-4B4A-4017-9294-F5EF9D678B67Q33599463-CD057382-A698-4148-9D46-0DC8A40BBD74Q33740638-D0A4F25D-95F6-4C80-A2DE-01744121B8E1Q33815676-F66A0FA3-EB19-4F1B-AE8E-2BC132B1BADFQ33853018-BF0FD253-4E48-4E6A-9180-FD80B854B276Q33973891-56513D56-9DCA-48F7-B3CA-8A9C0FAD9F3BQ34095816-626440E3-24AC-4796-AA5F-B50814C88B12Q34250632-866327F7-9489-408F-8222-EF0259347E42Q34272056-238B5EA1-C759-4EAE-88C4-F4F2ABFBDC2AQ34300668-D1785619-2C84-4A7E-8974-443B7E777253Q34446978-48EA1AF5-1734-42AE-B8D6-096F45190DFBQ34449901-5D0C2E1E-2F62-4AD3-9601-EBBB47053955Q34490225-0EAF1E9C-FB41-4417-B3AE-ED65EF5ED715Q34551489-0D6DD2FD-9E84-4857-9B80-AC74536E2F94Q34617936-9851CE4C-8D48-4320-8738-954492911E7EQ34629307-D41036E9-367E-4F84-BA29-286E35F50AA0
P2860
Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
name
Continued breast cancer risk r ...... omes of raloxifene evaluation.
@ast
Continued breast cancer risk r ...... omes of raloxifene evaluation.
@en
Continued breast cancer risk r ...... omes of raloxifene evaluation.
@nl
type
label
Continued breast cancer risk r ...... omes of raloxifene evaluation.
@ast
Continued breast cancer risk r ...... omes of raloxifene evaluation.
@en
Continued breast cancer risk r ...... omes of raloxifene evaluation.
@nl
prefLabel
Continued breast cancer risk r ...... omes of raloxifene evaluation.
@ast
Continued breast cancer risk r ...... omes of raloxifene evaluation.
@en
Continued breast cancer risk r ...... omes of raloxifene evaluation.
@nl
P2093
P2860
P356
P1476
Continued breast cancer risk r ...... omes of raloxifene evaluation.
@en
P2093
Farrerons J
Krueger KA
Lippman ME
Mellstrom D
P2860
P2888
P304
P356
10.1023/A:1006478317173
P407
P577
2001-01-01T00:00:00Z
P6179
1025713798